Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the "triple-negative" tumor status to disease-free and overall survival of women with epithelial ovarian cancer.
We assessed associations between steroid receptors including: estrogen-alpha, estrogen-beta, androgen receptor, progesterone receptor, the HER2 status and triple-negative epithelial ovarian cancer (ERα-/PR-/HER2-; TNEOC) status and survival in women with epithelial ovarian cancer. The study included 152 women with primary epithelial ovarian cancer. The status of steroid receptor and HER2 was determined by immunohistochemistry. Disease-free and overall survival were calculated and compared with steroid receptor and HER2 status as well as clinicopathological features using the Cox Proportional Hazards model. A mean follow-up period of 43.6 months (interquartile range=41.4 months) was achieved where 44% of patients had serous tumor, followed by mucinous (23%), endometrioid (9%), mixed (9%), undifferentiated (8.5%) and clear cell tumors (5.3%). ER-alpha staining was associated with grade II-III tumors. Progesterone receptor staining was positively associated with a Body Mass Index≥25. Androgen receptor positivity was higher in serous tumors. In stand-alone analysis of receptor contribution to survival, estrogen-alpha positivity was associated with greater disease-free survival. However, there was no significant association between steroid receptor expression, HER2 status, or TNEOC status, and overall survival. Although estrogen-alpha, androgen receptor, progesterone receptor and the HER2 status were associated with key clinical features of the women and pathological characteristics of the tumors, these associations were not implicated in survival. Interestingly, women with TNEOC seem to fare the same way as their counterparts with non-TNEOC.
Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas - Unicamp, Campinas, São Paulo, Brazil.
Maria Carolina Szymanski
MC
de Toledo
Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas - Unicamp, Campinas, São Paulo, Brazil. Electronic address: sarian@unicamp.br.
Luis Otavio
LO
Sarian
Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas - Unicamp, Campinas, São Paulo, Brazil.
Luis Felipe
LF
Sallum
Department of Pathology, Faculty of Medical Sciences, State University of Campinas - Unicamp, Campinas, São Paulo, Brazil.
Liliana Lucci Angelo
LL
Andrade
Laboratory of Experimental Pathology, CAISM - Unicamp, Campinas, São Paulo, Brazil.
José
J
Vassallo
Department of Pathology, Faculty of Medical Sciences, State University of Campinas - Unicamp, Campinas, São Paulo, Brazil; Laboratory of Experimental Pathology, CAISM - Unicamp, Campinas, São Paulo, Brazil.
Geisilene Russano
GR
de Paiva Silva
Laboratory of Experimental Pathology, CAISM - Unicamp, Campinas, São Paulo, Brazil.
Glauce Aparecida
GA
Pinto
Department of Pathology, Hospital do Câncer A C Camargo, Fundação Antonio Prudente de São Paulo, Brazil.
Fernando Augusto
FA
Soares
Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas - Unicamp, Campinas, São Paulo, Brazil.
Camila Dal Piccolo Pracchia
CD
Fonseca
Department of Obstetrics and Gynecology, Faculty of Medical Sciences, State University of Campinas - Unicamp, Campinas, São Paulo, Brazil.
Sophie F M
SF
Derchain
D000328:Adult; D000368:Aged; D000077216:Carcinoma, Ovarian Epithelial; D018572:Disease-Free Survival; D047628:Estrogen Receptor alpha / Q000378:metabolism; D047629:Estrogen Receptor beta / Q000378:metabolism; D005260:Female; D006801:Humans; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011944:Receptors, Androgen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D018719:Erb-b2 Receptor Tyrosine Kinases; D011944:Receptors, Androgen; D011980:Receptors, Progesterone; C506487:ESR1 protein, human; C508053:ERBB2 protein, human
Androgen receptor; Estrogen receptor; HER2; Ovarian cancer; Progesterone receptor; Tissue microarray; Triple negative